Lisocabtagene maraleucel significantly improved responses rates and survival outcomes among patients with relapsed or refractory chronic lymphocytic leukemia, according to findings presented at ASCO ...

Only a handful of stem cell therapies are currently approved by the F.D.A., mainly for treating blood cancer and immune ...

Our immune system is designed to protect us by recognizing and attacking infected or abnormal cells. However, cancer cells ...

Adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) face significant survival disparities and ...

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, ...

An international clinical trial shows an innovative CAR-T cell immunotherapy is promising against aggressive T cell cancers and has manageable side effects.

Allogeneic CAR-T cell therapy is produced using CRISPR gene editing from cells donated by healthy individuals.

Due to financial, logistical, and regulatory barriers, only two in 10 patients eligible for CAR T-cell therapy in the US ...

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, according to the results ...

Only approximately 2 out of 10 people in the US and 3 out of 10 people in Europe with certain rare, advanced blood cancers receive access to CAR T-cell therapy1,2,3 New roadmap report aims to inspire ...

Data on the efficacy and safety of chimeric antigen receptor T (CAR-T) cell therapy in this population remains limited. Methods: We retrospectively analyzed 25 adult patients with relapsed or ...

T-cell prolymphocytic leukemia (T-PLL) is an uncommon mature T-cell neoplasm characterized by the proliferation of abnormal lymphoid cells morphologically akin to prolymphocytes. 1 However, in some ...